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Summary. Background: Low molecular weight heparins
(LMWHs) constitute the mainstay of anticoagulant ther-
apy for pediatric venous thromboembolism (VTE). The
safety and effectiveness of dalteparin, an LMWH, has not
been established in children, and pediatric data on daltep-
arin for VTE are limited to one single-center experience.
Objective: To establish dose-finding (primary endpoint)
and efficacy/safety outcomes (secondary endpoints) in
children treated with dalteparin in a substudy of the
Kids-DOTT trial. Patients and methods: A prospective
multicenter trial using dalteparin subcutaneously twice
daily for acute VTE in children aged ≤ 21 years was con-
ducted under an investigator-held Investigational New
Drug application registered with the US Food and Drug
Administration. Initial weight-based dosing per protocol
was as follows: infants (< 12 months), 150 IU kg1; chil-
dren (1–12 years), 125 IU kg1; and adolescents (13–18
years), 100 IU kg1. Bleeding events were categorized
according to ISTH criteria. Descriptive non-parametric
statistics were employed for all analyses. Results: Eighteen
patients (67% male) were enrolled from January 2010 to
October 2013 across four centers. No supratherapeutic
levels were observed. Median (range) therapeutic doses by
age group were as follows: infants (n = 3), 180 IU kg1
(146–181 IU kg1); children (n = 7), 125 IU kg1 (101–
175 IU kg1); and adolescents (n = 8), 100 IU kg1
(91–163 IU kg1). The median duration of dalteparin use
was 48 days (range: 2–169 days), and the median follow-
up was 10.5 months (range: 2–35 months). There were no
related serious adverse events, no clinically relevant bleed-
ing events, and no symptomatic recurrent VTEs. Conclu-
sion: Dalteparin successfully achieved targeted anti-
factor Xa levels in 18 children and young adults with
acute VTE with a standardized age-based dosing regimen,
with a favorable safety and efficacy profile.
Keywords: dalteparin; low molecular weight heparin;
pediatrics; safety; venous thrombosis.
Background
Low molecular weight heparins (LMWHs) constitute the
mainstay of anticoagulant therapy for pediatric venous
thromboembolism (VTE) [1]. Both enoxaparin and dal-
teparin are marketed in the USA. Whereas enoxaparin is
used in the majority of stand-alone children’s hospitals
[1], dalteparin is used preferentially at many community
hospitals, owing to lower costs. Dalteparin is approved
by the US Food and Drug Administration (FDA) for
VTE prophylaxis in adult medical and surgical patients,
as well as for the treatment of VTE in adults with cancer.
The original published experience of dalteparin use in
pediatrics described 48 patients from Germany, 23 of
whom received dalteparin as a primary therapeutic anti-
coagulant medication [2]. This work provided pharmaco-
kinetic data supporting the need for weight-based dosing
of this agent in children, with dose per kilogram being
inversely related with patient age. No major bleeding
events occurred, and minor bleeding occurred in two of
48 children. Patients were followed for 3–6 months, and
recurrent VTE was not tracked. Given heightened recog-
nition of the need for investigation of antithrombotic
agents in special populations, including children, the
FDA has mandated that additional pediatric studies of
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dalteparin be performed. A postmarketing commitment
study on pediatric cancer-associated VTE treatment is
ongoing [3].
Most recently, Inamo et al. reported the use of contin-
uous intravenous infusion of dalteparin and oral aspirin
with and without intravenous immunoglobulin (IVIG) in
two retrospective cohorts of 238 Japanese children with
Kawasaki’s disease. They concluded that the antiangio-
genic activity of adjunctive dalteparin was associated with
a lower prevalence of coronary artery lesions and IVIG
resistance [4].
The present study was conducted as a subanalysis of a
prospective multicenter trial, the Evaluation of the Dura-
tion of Therapy for Thrombosis in Children trial (the
Kids-DOTT trial), whose objective is to evaluate the opti-
mal duration of anticoagulation for acute VTE in chil-
dren. The objective of the dalteparin substudy was to
establish dose-finding (primary endpoint) and efficacy/




This was an open-label, dose-finding pilot study of daltepa-
rin as primary treatment for VTE in children aged
0–21 years. This work was a subanalysis of a large, ongoing
multicenter randomized clinical trial (Kids-DOTT trial),
whose primary objective is to compare the efficacies
of short-duration (6 weeks) and conventional-duration
(3 months) anticoagulation in first-episode acute provoked
VTE patients in whom thrombus resolution/non-occlusive-
ness is evident following the first 6 weeks of anticoagulant
therapy [5]. The assignment of anticoagulant class (e.g.
LMWH and warfarin) in the Kids-DOTT trial, and
therefore for the dalteparin subanalysis, was made by
choice of treatment physician and patient/parent. During
predefined ‘dalteparin waves’ at each participating center,
when treatment with LMWH was selected by the patient/
clinician, the LMWH employed was dalteparin, as dis-
pensed through the investigational pharmacy at each site.
The study was conducted under FDA IND #77 923. The
study was approved by the Institutional Review Board of
each participating center, and parents/guardians of the
subjects gave their informed consent prior to enrollment.
Patients
Inclusion criteria were as follows: children aged from
birth to ≤ 21 years at the time of enrollment with recently
diagnosed (i.e. within 30 days of radiologic diagnosis)
first-episode provoked VTE. Major exclusion criteria
included known pulmonary embolism, use of thrombo-
lytic therapy, prior episode of VTE, history of cancer,
systemic lupus erythematosus, pregnancy at time of
enrollment, or severe anticoagulant deficiency as defined
by any of the following: protein C, < 20 IU dL1; anti-
thrombin, < 30 IU dL1; or protein S, < 20 IU dL1).
Materials and methods
Dalteparin (Fragmin; Eisai, Woodcliff Lake, NJ, USA)
was provided by the manufacturer. The initial weight-
based dosing per protocol was as follows: infants
(< 12 months), 150 IU kg1; children (1–12 years),
125 IU kg1; and adolescents (13–21 years), 100 IU kg1.
All doses were administered subcutaneously twice daily.
Routine anticoagulation monitoring with anti-factor Xa
levels was performed locally as clinically indicated, in
accordance with the standard of care at each institution,
and these results were collected for analysis. All three
sites utilized a chromogenic method (STA, Liquid Anti-
Xa assay) to measure anti-FXa activity (Diagnostica
Stago, Parsippany, NJ, USA). Sites were instructed to
adjust starting doses by 10–20%, if needed, to achieve the
goal of anti-FXa activity (4–6 h following the first,
second or third dose) of 0.5–1.0 U mL1.
The primary efficacy outcome was symptomatic recur-
rent VTE. This outcome was tracked via patient follow-
up visits at 6 weeks, 3 months, and 6 months, and via
brief interim telephone assessments for symptoms of con-
cern for possible recurrent VTE performed at 2, 4 and
5 months (at which times the need for patients to
promptly report symptoms of concern to their treating
physician was reinforced). Adverse events of particular
interest included: (i) anaphylaxis temporally related to
anticoagulant administration; and (ii) major bleeding.
Bleeding events were categorized according to ISTH crite-
ria, and major bleeding was defined as intracranial or ret-
roperitoneal bleeding, bleeding requiring major surgical
intervention under anesthesia, or clinically overt bleeding
from any site associated with a decline in hemoglobin
level of ≥ 2 g dL1 in a 24-h period [6].
The targeted sample size was 50 subjects, in order to
achieve adequate precision in descriptive statistics of out-
come measures, and was not powered for inferential sta-
tistics. However, accrual on the dalteparin substudy was
slower than projected, and hence the substudy was closed
upon completion of a 1-year extension in the grant-
funded period of the substudy. Descriptive non-paramet-
ric statistics were employed for all analyses.
Results and discussion
Eighteen patients (12 males and six females) were enrolled
in the dalteparin substudy from January 2010 to October
2013 across four US centers (Table 1). During this time-
frame, 69 patients were enrolled in the parent Kid-DOTT
trial. Of these 69 patients, 51 did not participate in
the dalteparin study, either because their enrollment did
not take place during a dalteparin wave, or because an
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alternative long-term anticoagulant (i.e. warfarin) was
selected by the treating physician. A variety of thrombotic
events were represented, with lower-extremity VTE
(n = 6), upper-extremity VTE (n = 4) and cerebral sinus
venous thrombosis (n = 4) being the most common. Age
ranged from 6 months to 19 years, with almost half
(n = 8) of the study population being in the adolescent
age group.
In the dalteparin patients, no supratherapeutic anti-FXa
levels were observed using the dosing protocol. The median
and range of therapeutic doses by age group were as follows:
infants (n = 3), 180 IU kg1 (146–181 IU kg1); children
(n = 7), 125 IU kg1 (101–175 IU kg1); and adolescents
(n = 8), 100 IU kg1 (91–163 IU kg1). All therapeutic dal-
teparin doses lower than that stipulated by the protocol
were attributable either to rounding to the nearest 100-unit
dose for the patient’s convenience, or to dose adjustment for
low body mass in obese patients (Table 1).
The median duration of dalteparin use was 48 days
(range: 2–169 days). Three patients received a dalteparin
course of > 90 days. It should be noted that prolonged
LMWH therapy is known to have a negative impact on
bone mineral density, and that the specific impacts of dal-
teparin on bone mineral density in pediatric patients and
on recovery after discontinuation are not well known [7].
All 18 enrolled patients in the dalteparin substudy were
observed throughout the prespecified adverse event fol-
low-up period of 3 months (maximum randomized dura-
tion of therapy) plus 10 days. The median follow-up was
10.5 months (range: 2–35 months), and during that time
there were no symptomatic recurrent VTEs. In a meta-
analysis of single-arm studies of the safety and efficacy of
LMWH, the incidence of recurrent VTE was 2.72% in a
population of 1433 children receiving LMWH for acute
treatment or secondary prophylaxis of VTE [8].
One patient died during participation in this study. The
death was deemed to be unrelated to the study drug dal-
teparin, and was attributed to sudden unexpected death
in epilepsy. This patient had a prior history of epilepsy.
In the dalteparin subgroup, there were no medication-
related serious adverse events and no clinically relevant
bleeding events. Two minor bleeding events (bruising and
epistaxis) were reported (11.1% of patients). There were
no reported adverse events pertaining to thrombocytope-
nia. In the LMWH meta-analysis referenced above, the
incidence of clinically relevant bleeding was 2.4% and the
incidence of minor bleeding was 9.6% [8].
The limitations of our study include a small sample size
resulting from suboptimal accrual, resulting in a lower
precision of outcome estimates than initially desired. The
inherent difficulties in accruing patients to clinical trials
of antithrombotic therapy in the pediatric population
have been well described [9]. Also, our population was
limited to patients with provoked, first-time VTE cared
for at tertiary-care pediatric centers, so the results may
not be generalizable to the broader population of pediat-
ric thrombosis patients. It should be noted that almost
half of the participants were adolescents, and only three
participants were infants. Owing to the small number of
infants, we cannot comment on dosing recommendations
for this age group, and neonatal studies of dalteparin are
urgently needed. The strengths of the study include its
prospective nature, standardized definitions, and close
tracking of clinical outcomes.
Table 1 Characteristics of 18 pediatric venous thromboembolism (VTE) patients treated with dalteparin
Age








0.5 4.4 M White/not Hispanic CSVT 181 25 CTR
0.5 8.2 M White/unknown Lower extremity 146 23 CTR
0.6 6.8 F White/not Hispanic Lower extremity 180 51 CTR
2 13.3 M White/Hispanic Jugular 175 45 CTR
2 12.6 F White/Hispanic Lower extremity 135 60 CTR
5 14.4 M White/not Hispanic Upper extremity 173 81 PTNP
8 27.6 M Other/Hispanic Upper extremity 125 169 CTR
8 30.2 F White/not Hispanic CSVT 124 48 PTNP
8 56.1 M Other/Hispanic CSVT 125 48 CTR
12 44.5 M Unknown/not Hispanic Jugular 101 14 PTNP
14 60.1 F White/not Hispanic CSVT 125 94 CTR
15 61.8 M American Indian Lower extremity 100 2 PTNP
16 43.4 F White/not Hispanic Lower extremity 100 39 CTR
17 106 M White/Unknown Lower extremity 94 100 CTR
17 40.2 M Other/not Hispanic Upper extremity 100 52 PTNP
18 76.4 M White/not Hispanic Hepatic 163 35 CTR
19 66.3 M Other/not Hispanic Upper extremity 100 55 CTR
19 98.9 F Black/not Hispanic Jugular 91 67 CTR
CSVT, cerebral sinus venous thrombosis; CTR, complete thrombus resolution; F, female; M, male; PTNP, persistent thrombus, non-progres-
sive (improved or stable).
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In conclusion, dalteparin successfully achieved targeted
anti-FXa levels in 18 children and young adults with
acute VTE with a standardized, age-based dosing regi-
men. Dalteparin showed a favorable safety and efficacy
profile, and efficacy and safety outcomes in our popula-
tion appear to be qualitatively similar to those in the
published pediatric literature on LMWH.
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